[1]ViridianAnnounces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED). Retrieved August 15, 2022, from网页链接 @药明康德内容团队报道 生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持...
Objective: Report results from the first cohort of TED patients treated with 2 intravenous infusions of 10 mg/kg VRDN-001 from our phase 1/2 double-masked randomized clinical trial (NCT05176639).Background: IGF-1R antagonism can reduce TED-related inflammation and proptosis. We are evaluating ...
VRDN-001 is a humanized IgG1魏 monoclonal antibody that binds to human insulin-like growth factor-1 receptor (IGF-1R) and inhibits its activation.Design/Methods: Our first phase 1/2 trial will be a randomized, placebo-controlled multiple ascending dose (MAD) study in healthy volunteers and ...
Objective: Report the interim safety and pharmacodynamic (PD) results for healthy volunteers from a phase 1/2 clinical trial (NCT05176639) evaluating VRDN-001 intravenously administered at 3–20 mg/kg.Background: Clinical and preclinical studies have confirmed insulin-like growth factor-1 receptor ...
VRDN-001 shut down IGF-1R signaling at concentrations that can be achieved with moderate clinical doses. The in vitro profile of VRDN-001 suggests favorable efficacy and exposure requirements for treatment of TED patients. A phase 1/2 trial for VRDN-001 in healthy volunteers and TED patients...